Page 2 - Efficacy Response News Today

A large RCT found testosterone replacement therapy more effective than placebo in middle-aged and older men with hypogonadism.

Nearly 15% of older men with hypogonadism experience anemia. TRAVERSE is the first trial to report the effects of testosterone replacement therapy (TRT) on anemia incidence in hypogonal men.

Trial findings help characterize the cardiovascular risk profile of testosterone-replacement therapy in at-risk men with hypogonadism.

Trial findings help characterize the cardiovascular risk profile of testosterone-replacement therapy in at-risk men with hypogonadism.

A phase 4 trial of men with hypogonadism in the US offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy.

The clinical trial found such therapy does not lead to an increase major adverse cardiac events for men with low testosterone.